Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H30N2O2 |
Molecular Weight | 318.4537 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN(C(C)C)[C@H]1COC2=C(C1)C(=CC=C2)C(=O)NC(C)C
InChI
InChIKey=UEAKCKJAKUFIQP-OAHLLOKOSA-N
InChI=1S/C19H30N2O2/c1-6-10-21(14(4)5)15-11-17-16(19(22)20-13(2)3)8-7-9-18(17)23-12-15/h7-9,13-15H,6,10-12H2,1-5H3,(H,20,22)/t15-/m1/s1
Molecular Formula | C19H30N2O2 |
Molecular Weight | 318.4537 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ebalzotan is a selective serotonin (5-HT1A) receptor agonist, was chosen by Astra in the early 1990s as a candidate drug for the treatment of depression and anxiety. It has a modest affinity for the 5-HT(7). In vivo, ebalzotan induced all the typical effects of a 5-HT(1A) receptor agonist in rats: it decreased 5-HT synthesis (5-HTP accumulation) and 5-HT turnover (measured as the ratio of 5-hydroxyindoleacetic acid/5-HT), increased corticosterone secretion, induced the 5-HT(1A) syndrome (flat body posture and forepaw treading), inhibited the cage-leaving response, and caused hypothermia. Ebalzotan had been in phase I clinical trial for the treatment of major depressive disorder. However, this study was discontinued.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:14 GMT 2023
by
admin
on
Fri Dec 15 15:29:14 GMT 2023
|
Record UNII |
WV4B56N49H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1742470
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
7065
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
DTXSID601029378
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
9797080
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
149494-37-1
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
C72746
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
WV4B56N49H
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
SUB06434MIG
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
Ebalzotan
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY | |||
|
100000080481
Created by
admin on Fri Dec 15 15:29:14 GMT 2023 , Edited by admin on Fri Dec 15 15:29:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|